In Section C, individuals will obtain ABBV-744 and oral navitoclax. In Segment D, individuals will receive ABBV-744 and ruxolitinib. Participants will receive treatment until eventually disease progression or the contributors are unable to tolerate the study drugs. - "Our study unveiled the essential purpose in the KLF16/MYC regulatory axis in https://tommyo887doz0.blogcudinti.com/profile